Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
Akingbemi W, Kurtz G, Yegya-Raman N, Plastaras JP, Schuster SJ, Chong EA. Akingbemi W, et al. Among authors: yegya raman n. Leuk Lymphoma. 2024 Jun;65(6):860-863. doi: 10.1080/10428194.2024.2322033. Epub 2024 Mar 7. Leuk Lymphoma. 2024. PMID: 38451075 No abstract available.
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, Feigenberg SJ. Iocolano M, et al. Among authors: yegya raman n. Cancer. 2024 Jun 1;130(11):2031-2041. doi: 10.1002/cncr.35230. Epub 2024 Jan 31. Cancer. 2024. PMID: 38294959
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Barsouk A, et al. Among authors: yegya raman n. Clin Lung Cancer. 2024 May;25(3):e161-e171. doi: 10.1016/j.cllc.2023.12.009. Epub 2023 Dec 22. Clin Lung Cancer. 2024. PMID: 38195320
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP, Cengel KA, Kao G, Teo BK, Langer CJ, Xiao Y, Bradley J, Feigenberg SJ, Yegya-Raman N. Friedes C, et al. Among authors: yegya raman n. Radiother Oncol. 2024 Jan;190:110030. doi: 10.1016/j.radonc.2023.110030. Epub 2023 Nov 24. Radiother Oncol. 2024. PMID: 38008414
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
Yegya-Raman N, Ho Lee S, Friedes C, Wang X, Iocolano M, Kegelman TP, Duan L, Li B, Berlin E, Kim KN, Doucette A, Denduluri S, Levin WP, Cengel KA, Cohen RB, Langer CJ, Kevin Teo BK, Zou W, O'Quinn RP, Deasy JO, Bradley JD, Sun L, Ky B, Xiao Y, Feigenberg SJ. Yegya-Raman N, et al. Radiother Oncol. 2024 Jan;190:110005. doi: 10.1016/j.radonc.2023.110005. Epub 2023 Nov 14. Radiother Oncol. 2024. PMID: 37972736
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, Yegya-Raman N. Friedes C, et al. Among authors: yegya raman n. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1435-1444. doi: 10.1016/j.ijrobp.2023.10.005. Epub 2023 Oct 21. Int J Radiat Oncol Biol Phys. 2024. PMID: 37866762
One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia.
Arkles J, Markman T, Trevillian R, Yegya-Raman N, Garg L, Nazarian S, Santangeli P, Garcia F, Callans D, Frankel DS, Supple G, Lin D, Riley M, Kumaraeswaran R, Marchlinski F, Schaller R, Desjardins B, Chen H, Apinorasethkul O, Alonso-Basanta M, Diffenderfer E, Kim MM, Feigenberg S, Zou W, Marcel J, Cengel KA. Arkles J, et al. Among authors: yegya raman n. Heart Rhythm. 2024 Jan;21(1):18-24. doi: 10.1016/j.hrthm.2023.10.005. Epub 2023 Oct 11. Heart Rhythm. 2024. PMID: 37827346
SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.
Anstadt EJ, Carmona R, Berlin E, Yegya-Raman N, Venigalla S, Reddy V, Williams GR, Leibensperger MR, Wojcieszynski A, Baumann BC, Lee MK, Plastaras JP, Furth EE, Mell LK, Metz JM, Ben-Josef E. Anstadt EJ, et al. Among authors: yegya raman n. Cancer. 2024 Feb 1;130(3):476-484. doi: 10.1002/cncr.35058. Epub 2023 Oct 12. Cancer. 2024. PMID: 37823514
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ. Friedes C, et al. Among authors: yegya raman n. Clin Lung Cancer. 2024 Jan;25(1):50-60.e6. doi: 10.1016/j.cllc.2023.09.002. Epub 2023 Sep 17. Clin Lung Cancer. 2024. PMID: 37813713
51 results